Nrx pharmaceuticals partners with mannkind corporation to develop zyesami™ (aviptadil) inhaler for respiratory conditions

Radnor, pa., aug. 4, 2021 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp) announced today it has signed an agreement with mannkind corporation to develop a dry powder formulation of zyesami™ (aviptadil), a synthetic form of human vasoactive intestinal peptide (vip), produced by the body to help protect cells against inflammatory conditions.
NRXP Ratings Summary
NRXP Quant Ranking